in statements I, II and III in reply *to* Rajya Sabha Unstarred Question No. 51 for 25-4-1988.

Price increase of Vitamins A ana C

674. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to refer to the. answer to Unstarred Question 3529 given in the Rajya Sabha on 28th March, 1988 and state:

(a) whether it is a fact that his Ministry ,flxed the prices of Vitamins A and C under DPCO, 1979;

(b) if so, the names of units whose production was studied along) with the date of study and price recommended by BICP;

(c) when was the price notified for each;

(d) whether it is a fact that producers have increased. the prices of these drugs:

(e) if so, the price under DPCO, 1979, present price and percentage increase in each case;

(f) whether it is a fact that number of representations have baen submitted for inclusion . of these drugs under price control;

(g) whether it is also a fact that Kelker Committee recommended for price control of these drugs and have also confirmed their recommendation in reply to those who submitted representations; and

(h) if *so,* how his Ministry has exempted these drugs from price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO). (a) Yea, Sir. .

(b) to (e) The required details t& the extent of information, are given

			Price fixed under DPCO lOTQ	Current	
J.	Vitamin A Acetate Dry Powder 0.5 MlU/gm	1000 MIU	1297.86	2100.00	61.8
IT.	Vit. A Palmitate 1 MlU/gm HI,	1000 MIU	990.35	1300.00	31.2
Vit. A Palmitate . IV.	Vitamin B	1000 MIU	1020.67	1300.00	27.4
(1.7 MIU/gm)				*320.00*	45.8

(Ambalal Sarahhai Ltd)

(f) to (h) The requisite information has already been furnished to the Rajya Sabha in reply to the Unstarred Question No. 51 on 25th April 1988.

Production of Noosporla range __ formulations

675. SHRI CHANDRDYA PRASAD TRIPATHI: -Will the Minister of INDUSTRY "be nleased to state: .

(a) what is the composition of Neosporin, Avaforen, Acetan, Gly-nase, ndamin; Nebasulf, Flucort, Leadercort, Maftal, Naprosyn Arta-gen, Equagesic, Actifed, Arflur; Mclleril and fosipan along with the name of the manufacturer and therapeutic indication of each;

(b) names of bulk drugs going into the manufacture of these medicines allowed for production alone with

names of producers, capacity sanctioned to each of each drug and production of each drug during the last three years, year-wise;

(c) whether any of these drugs are allowed for import under OGL;

(d) if BO, names of those drugs;

(e) whether these products were under price control under DPCO 1979;

(f) if so, names of those products, price fixed for each along with present price and percentage change in each case;

(g) whether any one of these products have been price decontrolled; and

(h) if go, names and basis for decontrol?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO). , (a) and (b) Details to the extent available are given in the attached statement-! and II. *(See* below).

(c) and (d) Names of drugs allowed for import under OGL are given in the Export-Import Policy during the period April, 1988 to March, 1994.

(e) Formulations were categorised as per the provisions of Drugs (Prices control) Order, 1979.

(f) The required details pertaining to DPCO, 1979 are not readily avail able..

(g) and (h) The status of price control of these formulations depend* upon the various provisions of DPCO 1987, Guidelines issued thereundei and exemption granted to small scale industrial units, etc.

Statement—I

SI. No	Name of the formulations/Company *t.*	Major ingredients	Therapeutic Indications
1	2	3	4
1	*Neosporin Ointment* Burroughs Wellcome	Polymyxin-B Sulphate Zine Bacitracfn Neomycin Sulphate	External Infections
2	*Neosporin Powder* Burroughs Wellcome	Do.	External Infections
3	*Neosporin Eye Drops* Burroughs Wellcome	Polymyxin-B Sulphate Neomycin Sulphate Gramicidin	External Bacterial Infection of Eye
4	Avafortan	Avapyrazone, Analgin	Spasmodic Pains In Gastro-Westlnal. Biliary and urogenital tracts.
5	Aceten (Wockhardt)	Captopril	All grades and varieties of Hypertension
6	Glynase (US Vitamins)	Glipizide	Maternity onset diabetes mellitus
7.	Ildamen. (German Remedies)	Oxyfedrine	Angina Pectoris. ceronary insufficiency, Myocardial infarction.
8	Nebasulf Eye Ointment(Pfizer)	Neomvcin Sulphate Bacitracin. Sulphacetamide	Superficial ocular infections

J	2	3	4
9	Nebasulf Skin Onitment (Cynamid)	Neomycin Sulphate, Bacitracin, Sulphacetamide	Skin Infections
10	Ledercbrt-Onltment (Cynamid)	Triamcinolone	Symptomatic relief of various dermateses
11	Ledercort Tablets (Cynamid)	Triamcinolone	Rheumatoid Arthritis Allergies.
12	Artagon (Ranbaxy)	Naproxen	Rheumatoid Arthritis Cbteorthrssis, Ankylosing spondilitis
13.	Equagesie (Wyeth)	Ethoheptazfne, Meprobamate Acetyl Salicylic Acid	Pain accompanied by anxiety, tension musculespiletal disorders & Dysmenorrhoea.
14.	Actifed (Burroughs Wellcome)	Triprolidine, Pseudo-Ephedrine	Nasal and respiratory congestion, - coirmon cold, Hay fever.
15.	Melleril (Sandoi)	Thioridazine	Schizophrenia, manic psychoses. As an ad-junct to short term management of psy-choneurosis. Senile confusions & beha-vioural disorders.

Statement- II .

Name of drug	Name of company	A/c Unit	Capacity per annum	Production 1984-85	1985-86	1986.87
1	2	3	4	5	6	7
Aspirin	1. Alta Labs	T	1120	788.43	1012.57	608.45
	2. Andhra Sugar	T	500	272.90	433.60	357.30
	3. Shrlshma Fine Chemicals	T	1000		68.16	869.63
	4 KSDP	T	1000			
	5. Amar Dye-Chem	T	300			
Sulphacetamide	1. IDPJL	T	80	39.45	27.6	38.81
	2. E.I.P.W.	T	24	8.01	632	9.69
Metamizoh	1. IDPL	T	400	355.87	208.32	136.35
	2. Eupherlc	T	100			
	3. zpsroc	T	100			
	4. Bihar State Pharmaceutical & Dev. Corpa.	T	30			
	5. CJpla.	T	5			
Meprobamato	Geoffery Manners	T	6.46	Not Monitered		[
Neomycin	Synbiotlcs	T	3			

1	2	3	4	.5	6	7
Psuedogphedrine Hcl.						
	1. Burroughs Wellcome	T	2			
	2. Malladi Drugs	T	20			
Ethopheptazine Citrate	Wyelh Labs		i Not specified			
Naproxen	1. Pefco	T	10			
	2. RallJs	T	5			
	3. Searle	T	10			
	4. Standard	T	3		.Not Monitered.	
	5. South India Research Institute	*T*	100			
	6. Siris India	T	12			
	7. Rama Organics	T	20			
	8. Malie Pharmaceuticals •	T	24			
	9. C.P.C. Pharmaceuticals	T	20			
	10. V.K. RisM	T	12			
	11. N.A. Rattafah	T.	10			

Price control on single Ingredient Vitamin Formulations

676. DR. (SHRIMATI) SAROJINI' MAHISHI: Will the Minister of INDUSTRY be pleased bo state;

(a) whether it is a fact that KelkaT Committee recommended for price decontrol *at* single ingredient brand ed vitamin formulations;

(b) whether it is also a fact that these products do not fulfil any exclusion criteria;

(c) whether it is a fact that a number of representations have been made by Consumer Association and other to reconsider this recommendation as these products do not qualify for exemption;

(d) if so, what are the details of such representations;

(e) whether these representations have been considered by Kelkar Committee; and

(f) if so, the decision taken on each representations?

THE MINISTER OF INDUSTRY (SHRl J. VENGAL RAO). (a) Yes, Sir.

(b) Yes, Sir

(c) to (f) The requisite information has already been furnished to the Rajya Sabha in reply to Unstar-red Question No. 51 on 25th April, 1M8..

Prices of Chlorthalldine

677. DR. (SHRIMATI) SAROJINl MAHISHI: Will the Minister of INDUSTRY be pleased to state:

(a) the names of the cornpaniei allowed to produce Chlorthalidine,